Scientific Evidence

A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management

Apr 2024

Diagnostic GEP tests help guide clinical decision-making in a variety of diagnostically ambiguous or clinicopathologically discordant scenarios.

Author: Alexander Witkowski, MD, PhD, et al.

Publication: Future Medicine

23-gene expression profile (GEP) testing for diagnosis of cutaneous melanocytic lesions in a Medicare-eligible population

Mar 2024

The high accuracy and clinical utility of the 23-GEP test demonstrated across multiple prior studies are applicable to the Medicare-eligible population.

Author: Jose A Plaza, MD, et al.

Publication: Poster, presented at the 2023 College of American Pathologist (CAP) Annual Meeting

Diagnostic discordance among histopathological reviewers for difficult-to- diagnose melanocytic lesions

Jan 2024

Author: Hosler G, et al.

Publication: Poster, presented at the 2024 Winter Clinical Dermatology Conference - Hawaii®, Honolulu, Hawaii, January 12-17, 2024

Diagnostic utility of the 23-gene expression profile test for an atypical intradermal melanocytic proliferation

Dec 2023

A case report describing how MyPath GEP testing leads to diagnostic clarity in a histopathologically ambiguous melanocytic lesion on the face of a 34-year-old man.

Author: Marks E, et al.

Publication: Future Medicine

A Physician’s Guide to the Use of Gene Expression Profile Ancillary Diagnostic Testing for Cutaneous Melanocytic Neoplasms

Dec 2023

A real-world assessment of common use scenarios of MyPath GEP testing by dermatopathologists and dermatologists to achieve definitive diagnoses and personalized patient management plans.

Author: Marks E, et al.

Publication: Journal of Clinical and Aesthetic Dermatology

Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi-center performance cohort of cutaneous melanocytic neoplasms

Nov 2023

Accuracy data in an independent, multi-center cohort of 2512 melanocytic lesions

Author: Goldberg M, et al.

Publication: Skin

Performance of the 23-gene expression profile (23-GEP) test by histopathological evaluation in an independent, multi center performance cohort of cutaneous melanocytic neoplasms

Oct 2023

Author: Goldberg M, et al.

Publication: Poster, presented at the 2023 ASDP Annual Meeting

Asymmetrical pigmented lesion with high clinical suspicion for melanoma

Jun 2023

A 27-year-old female patient was seen by a primary care physician who recommended follow-up with a dermatologist for assessment of a concerning melanocytic lesion.

Multi-colored lesion with uncertain malignant potential

Jun 2023

Conflicting clinical and histopathological findings are resolved with the use of GEP test results.

Irregular papule with atypical histopathological findings and borderline/uncertain diagnosis

Jun 2023

Definitive diagnosis cannot be reached in an irregular, raised papule on the dorsal foot.

Atypical melanocytic proliferation on sensitive preauricular check

Jun 2023

Histopathological assessment of a melanocytic lesion on the check could not definitively rule out melanoma leading to the use of GEP prior to determining surgical management.

Abnormally pigmented lesion with uncertain malignant potential

Jun 2023

With benign GEP results, dermatopathologist adjusts diagnosis to a benign neoplasm and patient avoids re-excision.